Via Oncology is taking several steps to implement value into clinical pathways programs, explained President and CEO Kathleen Lokay.
Via Oncology is taking several steps to implement value into clinical pathways programs, explained President and CEO Kathleen Lokay.
Transcript
How is Via Oncology working to implement value into clinical pathway programs?
It’s really at several levels. One is that we’ve always taken the approach that we want the committees if everything else is really comparable in terms of efficacy and toxicity, we want the committees to drive to the approach that is the least costly to the patient and the payer. So we’ve always incorporated value at that third test. What we’re also hearing from our customers is that they want more information to be able to have shared discussions with patients when maybe the thing that has better efficacy maybe has a price tag that is just too high for that patient. So we’ve developed a cost analyzer tool to let the physicians have access to the information in those shared decision-making situations.
And then the third thing is our committees are increasingly carving out patient presentations for not clinical presentations, but financial presentations so we may have a pathway branch for a patient who can’t afford the copay on an oral drug and will instead provide an IV alternative that has a lower copay or no copay so the committees have the ability to really create those more value based scenarios based on patient preference.
What we’re not doing, and I don’t know when we will, is we’re not asking the committees to decide whether three extra months of survival is worth a certain price tag. We don’t feel that there is a societal agreement on what that is today so we certainly don’t want to be asking our committees to be making that judgement call.
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
AUA Session Highlights the General Urologist’s Role in Gender-Affirming Care
May 7th 2024During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.
Read More